APA (7th ed.) Citation

C, H., BA, F., A, K., S, K., R, G., J, M., . . . LA, P. (2022). A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer. Medical oncology (Northwood, London, England), 39(4), 49. https://doi.org/10.1007/s12032-021-01637-0

Chicago Style (17th ed.) Citation

C, Hamm, et al. "A Prospective Phase II Clinical Trial Identifying the Optimal Regimen for Carboplatin Plus Standard Backbone of Anthracycline and Taxane-based Chemotherapy in Triple Negative Breast Cancer." Medical Oncology (Northwood, London, England) 39, no. 4 (2022): 49. https://doi.org/10.1007/s12032-021-01637-0.

MLA (9th ed.) Citation

C, Hamm, et al. "A Prospective Phase II Clinical Trial Identifying the Optimal Regimen for Carboplatin Plus Standard Backbone of Anthracycline and Taxane-based Chemotherapy in Triple Negative Breast Cancer." Medical Oncology (Northwood, London, England), vol. 39, no. 4, 2022, p. 49, https://doi.org/10.1007/s12032-021-01637-0.